cAMR
Conditions
Interventions
Test group:Telitacicept
Sponsors
Xiangya Hospital of Central South University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. CAMR was diagnosed by pathological biopsy; 2. Having undergone at least one round of routine anti rejection therapy (hormone shock+IVIG ± rituximab); During the follow-up process, the patient experienced symptoms such as unstable creatinine (increased by over 30%) and worsening proteinuria; Clinical considerations or needle biopsy confirm the persistent or progressive progression of cAMR lesions. 3. The patient voluntarily signs an informed consent form.
Exclusion criteria
Exclusion criteria: 1. Uncontrolled infected patients; 2. Individuals who are known to be allergic to the study drug; 3. Pregnant or recently preparing pregnant women, lactating women; 4. Patients who are currently suffering from active hepatitis or have had a history of severe liver disease or illness; 5. Patients with active or recurrent gastrointestinal ulcers; 6. Subjects participating in clinical research on other drugs; In addition to the above, the researchers have determined that there are other reasons that are not suitable for participating in this clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in urine protein and eGFR from baseline at week 24; | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in DSA levels and renal pathology scores from baseline at week 24;Changes in renal pathological score from baseline at 24 weeks; | — |
Countries
china
Contacts
Public ContactDing Xiang
Xiangya Hospital of Central South University
Outcome results
None listed